Search Result

Results for "

IR injury

" in MedChemExpress (MCE) Product Catalog:

標的別:	Adrenergic Receptor (2) Akt (5) Aldose Reductase (1) Amyloid-β (2) AP-1 (1) Apoptosis (10) Arp2/3 Complex (1) Autophagy (1) Biochemical Assay Reagents (1) Caspase (1) Cholinesterase (ChE) (2) Complement System (2) Dynamin (1) Endogenous Metabolite (3) Epigenetic Reader Domain (1) ERK (1) Ferroptosis (4) Fluorescent Dye (1) FOXO (1) Glutathione Peroxidase (2) IRE1 (1) Isotope-Labeled Compounds (3) JAK (1) JNK (2) Keap1-Nrf2 (1) MAP3K (2) MDM-2/p53 (3) MyD88 (1) NADPH Oxidase (1) NF-κB (6) NOD-like Receptor (NLR) (1) Orphan GPCR (1) p38 MAPK (1) Parasite (1) Phosphatase (1) Phospholipase (1) PI3K (2) PKA (1) Protease Activated Receptor (PAR) (2) Reactive Oxygen Species (ROS) (8) Reference Standards (8) ROS Kinase (2) SGLT (6) Sirtuin (2) SOD (1) STAT (2) Toll-like Receptor (TLR) (2) VEGFR (3)
研究分野別:	Cancer (14) Cardiovascular Disease (15) Endocrinology (2) Infection (1) Inflammation/Immunology (20) Metabolic Disease (11) Neurological Disease (11)

標的別:

Adrenergic Receptor (2)

Akt (5)

Aldose Reductase (1)

Amyloid-β (2)

AP-1 (1)

Apoptosis (10)

Arp2/3 Complex (1)

Autophagy (1)

Biochemical Assay Reagents (1)

Caspase (1)

Cholinesterase (ChE) (2)

Complement System (2)

Dynamin (1)

Endogenous Metabolite (3)

Epigenetic Reader Domain (1)

ERK (1)

Ferroptosis (4)

Fluorescent Dye (1)

FOXO (1)

Glutathione Peroxidase (2)

IRE1 (1)

Isotope-Labeled Compounds (3)

JAK (1)

JNK (2)

Keap1-Nrf2 (1)

MAP3K (2)

MDM-2/p53 (3)

MyD88 (1)

NADPH Oxidase (1)

NF-κB (6)

NOD-like Receptor (NLR) (1)

Orphan GPCR (1)

p38 MAPK (1)

Parasite (1)

Phosphatase (1)

Phospholipase (1)

PI3K (2)

PKA (1)

Protease Activated Receptor (PAR) (2)

Reactive Oxygen Species (ROS) (8)

Reference Standards (8)

ROS Kinase (2)

SGLT (6)

Sirtuin (2)

SOD (1)

STAT (2)

Toll-like Receptor (TLR) (2)

VEGFR (3)

研究分野別:

Cancer (14)

Cardiovascular Disease (15)

Endocrinology (2)

Infection (1)

Inflammation/Immunology (20)

Metabolic Disease (11)

Neurological Disease (11)

阻害剤およびアゴニスト

生化学アッセイ試薬

ペプチド

阻害性抗体

天然物

同位体標識化合物

製品番号	製品名	Target	研究分野	構造式

HY-10450

Dapagliflozin 65+ Cited Publications BMS-512148	SGLT	Metabolic Disease Cancer
Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

HY-W250113

Zymosan A 2 Publications Verification Zymosan A from Saccharomyces cerevisiae	Toll-like Receptor (TLR)	Inflammation/Immunology
Zymosan A (Zymosan A from Saccharomyces cerevisiae) is a TLR2 agonist, that targeting TLRs can prevent and suppress IR-induced intestinal injury. Zymosan A exhibits a significant radioprotective effect, and protects IR-induced intestinal injury in mice. Zymosan A promotes the regeneration of intestinal stem cells (ISCs), after IR injury .

HY-N2037

Higenamine 5+ Cited Publications Norcoclaurine; Demethyl-Coclaurine	MAP3K MDM-2/p53 Adrenergic Receptor ROS Kinase Apoptosis	Cardiovascular Disease Endocrinology
Higenamine (Norcoclaurine), a β2-AR agonist with antioxidant capability, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine is also a α1-adrenergic receptor antagonist with hypotensive effect. is a selective LSD1 inhibitor (IC₅₀=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine protects myocyte Apoptosis and ischemia/reperfusion (I/R) injury through selective activation of beta2-adrenergic receptor (β2-AR). Higenamine also reduces I/R-induced myocardial infarction in mice. Higenamine can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

HY-10450A

Dapagliflozin ((2S)-1,2-propanediol, hydrate) 65+ Cited Publications BMS-512148 (2S)-1,2-propanediol, hydrate	SGLT	Metabolic Disease Cancer
Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury .

HY-P99116

Faricimab RG7716; RO-6867461	VEGFR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .

HY-125773

β-cyano-L-Alanine Beta-cyano-l-alanine	Endogenous Metabolite	Neurological Disease
β-cyano-L-Alanine (Beta-cyano-l-alanine), a nitrile of widespread occurrence in higher plants, is enzymatically produced by cyanoalanine synthase from cyanide and cysteine as substrates . β-cyano-L-Alanine abolishes the protective effect of ethanol on cerebral ischemia/reperfusion (I/R) injury .

HY-N0615

Notoginsenoside R1 2 Publications Verification Sanchinoside R1; Sanqi glucoside R1	Amyloid-β Apoptosis	Others
Notoginsenoside R1 (Sanchinoside R1), a saponin, is isolated from P. notoginseng. Notoginsenoside R1 exhibits anti-oxidation, anti-inflammatory, anti-angiogenic, and anti-apoptosis activities. Notoginsenoside R1 provides cardioprotection against ischemia/reperfusion (I/R) injury. Notoginsenoside R1 also provides neuroprotection in H₂O₂-induced oxidative damage in PC12 cells .

HY-175032

ATF3-IN-1	Ferroptosis Epigenetic Reader Domain Reactive Oxygen Species (ROS) Glutathione Peroxidase	Cardiovascular Disease Neurological Disease
ATF3-IN-1 is a ferroptosis and ATF3 inhibitor. ATF3-IN-1 inhibits oxidative stress and ferroptosis through the ATF3/SLC7A11/GPX4 pathway, exerting anti-ischemic stroke effects. ATF3-IN-1 can attenuate ischemia/reperfusion (I/R) injury and improve neuronal survival. ATF3-IN-1 has neuroprotective effects and can be used to study ischemic stroke .

HY-N2081

Skimmianine 3 Publications Verification	Cholinesterase (ChE) PI3K Akt NF-κB	Neurological Disease Inflammation/Immunology Cancer
Skimmianine is an orally active furoquiniline alkaloid present mainly in the Rutaceae family. Skimmianine has analgesic, antispastic, sedative, and anti-inflammatory properties. Skimmianine inhibits acetylcholinesterase (AChE) (IC₅₀ = 8.6 μg/mL). Skimmianine exhibits cytotoxicity against a variety of cancer cell lines and genotoxicity. Skimmianine has antioxidant and anti-inflammatory effects on ischemia-reperfusion (IR) injury. Skimmianine exerts anti-inflammatory effects through activation of the phosphatidylinositol-3-kinase (PI3K)-protein kinase B (AKT) pathway. Skimmianine is neuroprotective by targeting the NF-κB activation pathway to prevent neuroinflammation. Skimmianine inhibits the release of histamine, intracellular Ca ²⁺ signaling and protein kinase C signaling .

HY-19696B

Tauroursodeoxycholate dihydrate Maximum Cited Publications 104 Publications Verification Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate	Caspase Apoptosis Endogenous Metabolite IRE1 NF-κB JNK Reactive Oxygen Species (ROS) Akt	Neurological Disease Metabolic Disease Inflammation/Immunology
Tauroursodeoxycholate dehydrate is an orally active taurine conjugate of Ursodeoxycholic acid (HY-13771). Tauroursodeoxycholate dehydrate inhibits caspase-3/7, Apoptosis, IRE1α/TRAF2/NF-κB, prevents JNK phosphorylation, inhibits ROS generation, and activates Akt signaling. Tauroursodeoxycholate dehydrate prevents cataract formation, reduces renal tubular damage in type 2 diabetic mice, reduces I/R injury in liver, and inhibits intestinal inflammation and barrier disruption in nonalcoholic fatty liver disease .

HY-118530

Bucillamine 2 Publications Verification SA96; Thiobutarit	VEGFR	Cardiovascular Disease Inflammation/Immunology
Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic agent with antiangiogenic properties. Bucillamine can protect against Ischemia/reperfusion (I/R) injury in high-risk organ transplants. Bucillamine inhibits the production of VEGF. Bucillamine can be used for the research of choroidal neovascularization (CNV) and rheumatoid arthritis (RA) .

HY-161119

Drpitor1a	Dynamin Reactive Oxygen Species (ROS)	Cardiovascular Disease Cancer
Drpitor1a is a potent Drp1 inhibitor. Drpitor1a inhibits mitochondrial ROS production, preventes mitochondrial fission, and improves right ventricular diastolic dysfunction during IR (ischemia reperfusion) injury. Drpitor1a has the potential for the research of lung cancer ^[1]

HY-W002942

Ferroptosis-IN-21 1,2,3,4-Tetrahydroquinolin-8-ol; 8-hydroxy-1,2,3,4-tetrahydroquinoline	Ferroptosis Reactive Oxygen Species (ROS)	Inflammation/Immunology
Ferroptosis-IN-21 is a ferroptosis inhibitor that protects against renal I/R injury by suppressing ferroptosis and directly scavenging peroxyl radicals. Ferroptosis-IN-21 displays broad-spectrum anti-ferroptotic efficacy across multiple inducers in renal tubular epithelial cells, with nanomolar potency and robust suppression of lipid Reactive Oxygen Species (ROS). Ferroptosis-IN-21 significantly ameliorates renal I/R injury in mice, reducing histological damage, functional impairment, and inflammatory cytokine expression, while decreasing lipid peroxidation biomarkers such as 4-hydroxynonenal. Ferroptosis-IN-12 can be used for research in the field of ferroptosis-targeted drug development .

HY-145237

BM213 3 Publications Verification	Complement System Apoptosis Reactive Oxygen Species (ROS)	Cancer
BM213 is a selective C5aR agonist, with an EC₅₀ of 59 nM. BM213 specifically activates the C5a-C5aR1 axis, which in turn promotes neutrophil extracellular trap (NET) formation and exacerbates inflammatory responses. BM213 significantly induces ventricular dilationin, promotes myocardial ROS production, and induces cardiomyocyte apoptosis in rats. BM213 can be used for the study of myocardial ischemia/reperfusion (I/R) injury .

HY-N2282

Zingiberen newsaponin Zingiberensis newsaponin	Aldose Reductase JAK STAT Autophagy Apoptosis NF-κB SOD Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Zingiberen Newsaponin (Zingiberensis newsaponin) is an orally active type of steroid saponin compound. Zingiberen Newsaponin exerts anti-hepatocellular carcinoma (HCC) effects by inhibiting autophagy and the AKR1C1/JAK2/STAT3 pathway. Zingiberen Newsaponin activates oxidative stress (upregulates ROS and MDA) and mitochondrial pathways, promoting cancer cell apoptosis. Zingiberen Newsaponin alleviates cerebral ischemia-reperfusion (I/R) injury by decreasing the concentration of pro-inflammatory cytokines and inhibits NF-κB. Zingiberen Newsaponin can enhance the activity of SOD, eliminate free radicals and protect nerve cells. Zingiberen Newsaponin induces platelet aggregation .

HY-115062

MJ33 lithium salt	Phospholipase NADPH Oxidase p38 MAPK Akt NF-κB AP-1 Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology Cancer
MJ-33 lithium salt is a competitive phospholipase A₂ (PLA₂) inhibitor with an IC₅₀ of 0.3 μM. MJ-33 lithium salt inhibits NOX2 activation and reduces ROS production by blocking the PLA₂ activity of Prdx6. MJ-33 lithium salt effectively inhibits the activity of acidic PLA₂ (pH 4.0) and reduces the degradation of alveolar surfactant phosphatidylcholine (PC), but exerts no effect on alkaline PLA₂ (pH 8.5). MJ-33 lithium salt significantly alleviates lung oxidative injury induced by ischemia-reperfusion (I/R). MJ-33 lithium salt significantly inhibits the invasion, migration and adhesion abilities of prostate cancer cells by suppressing the MAPK, AKT, NF-κB and AP-1 signaling pathways. MJ-33 lithium salt can be used for the research of ROS-related diseases and prostate cancer .

HY-E70008

Lumbokinase	Sirtuin	Inflammation/Immunology
Lumbokinase attenuates myocardial ischemia-reperfusion (I-R) injury through the activation of Sirt1 signaling, and thus enhances autophagic flux and reduces I-R-induced oxidative damage, inflammation and apoptosis .

HY-12829

SR-3306 1 Publications Verification	JNK	Neurological Disease Metabolic Disease Inflammation/Immunology
SR-3306 is a brain-penetrant and selective pan-JNK (JNK1/2/3) inhibitor. SR-3306 is a neuroprotective agent that can be used for the study of Parkinson's disease, ischemia/reperfusion (I/R) injury and obesity .

HY-10450R

Dapagliflozin (Standard) BMS-512148 (Standard)	Reference Standards SGLT	Metabolic Disease Cancer
Dapagliflozin (Standard) is the analytical standard of Dapagliflozin. This product is intended for research and analytical applications. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

HY-P5875A

P4pal10 TFA	Protease Activated Receptor (PAR)	Cardiovascular Disease Inflammation/Immunology
P4pal10 TFA is the TFA salt form of P4pal10 (HY-P5875). P4pal10 TFA is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 TFA inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 TFA reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 TFA ameliorates the injury in rats myocardial ischemia/reperfusion (I/R) models .

HY-177249

Salvianolic acid A derivative-1	Arp2/3 Complex	Cardiovascular Disease
Salvianolic acid A derivative-1 (Compound SAA-30) is a orally active derivative of Salvianolic acid A (HY-N0318). Salvianolic acid A derivative-1 binds to transgelin with a K_D of 2.39 μM. Salvianolic acid A derivative-1 promotes cell contractions by facilitating the aggregation of actin. Salvianolic acid A derivative-1 can be used for prevention of myocardial ischemia or other diseases associated with IR tissue injuries .

HY-P99886

Pexelizumab h5G1. 1-SC	Complement System Apoptosis	Cardiovascular Disease Neurological Disease
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .

HY-121988

INF4E	NOD-like Receptor (NLR)	Inflammation/Immunology
INF4E is a potent NLRP3 inflammasome inhibitor. INF4E inhibits caspase-1 and NLRP3 ATPase activities. INF4E shows protection against the IR-induced myocardial injury and dysfunction .

HY-151109

IR-990	Fluorescent Dye	Others
IR-990 is an activatable NIR-II fluorescent probe with an acceptor-π-acceptor (A-π-A) skeleton for real-time detection of H₂O₂ in vivo. IR-990 is a powerful diagnosis of agent-induced liver injury (DILI) .

HY-W414644

Fluacrypyrim	Parasite STAT Phosphatase MDM-2/p53 Apoptosis	Infection Neurological Disease Inflammation/Immunology Cancer
Fluacrypyrim, a Miticide, is a STAT3 inhibitor. Fluacrypyrim significantly increases the protein tyrosine phosphatases(PTPs) activity. Fluacrypyrim inhibits the growth of leukemia cells by a predominant G1 arrest with significant decrease of the protein and mRNA levels of cyclin D1. Fluacrypyrim selectively inhibits STAT3 signaling, inducing growth arrest and apoptosis in STAT3-dependent cancer cells. Fluacrypyrim mitigates IR-induced hematopoietic system injury mainly by preventing apoptosis in the HSCs. Fluacrypyrim demonstrates significant analgesic and anti-inflammatory effects by inhibiting uterine smooth muscle contraction and inflammatory responses .

HY-N2081R

Skimmianine (Standard)	Reference Standards Cholinesterase (ChE) PI3K Akt NF-κB	Neurological Disease Inflammation/Immunology Cancer
Skimmianine (Standard) is the analytical standard of Skimmianine. This product is intended for research and analytical applications. Skimmianine is an orally active furoquiniline alkaloid present mainly in the Rutaceae family. Skimmianine has analgesic, antispastic, sedative, and anti-inflammatory properties. Skimmianine inhibits acetylcholinesterase (AChE) (IC₅₀ = 8.6 μg/mL). Skimmianine exhibits cytotoxicity against a variety of cancer cell lines and genotoxicity. Skimmianine has antioxidant and anti-inflammatory effects on ischemia-reperfusion (IR) injury. Skimmianine exerts anti-inflammatory effects through activation of the phosphatidylinositol-3-kinase (PI3K)-protein kinase B (AKT) pathway. Skimmianine is neuroprotective by targeting the NF-κB activation pathway to prevent neuroinflammation. Skimmianine inhibits the release of histamine, intracellular Ca ²⁺ signaling and protein kinase C signaling .

HY-N2037R

Higenamine (Standard) Norcoclaurine (Standard); Demethyl-Coclaurine (Standard)	Reference Standards MAP3K MDM-2/p53 Adrenergic Receptor ROS Kinase Apoptosis	Cardiovascular Disease Endocrinology
Higenamine (Norcoclaurine), a β2-AR agonist with antioxidant capability, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine is also a α1-adrenergic receptor antagonist with hypotensive effect. is a selective LSD1 inhibitor (IC50=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine protects myocyte Apoptosis and ischemia/reperfusion (I/R) injury through selective activation of beta2-adrenergic receptor (β2-AR). Higenamine also reduces I/R-induced myocardial infarction in mice. Higenamine can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

HY-168065

Keap1-Nrf2-IN-22	Keap1-Nrf2	Inflammation/Immunology
Keap1-Nrf2-IN-22 (compound 19) is a Keap1-Nrf2 inhibitor， with a K_D2 value of 42.2 nM for Keap1. Keap1-Nrf2-IN-22 can be used for the study of acute lung injury (ALI) and cerebral ischemia/reperfusion (I/R) injury .

HY-W783623

1,3-Didocosahexaenoyl glycerol DG(22:6/0:0/22:6); 1,3-Didocosahexaenoin	Biochemical Assay Reagents	Cardiovascular Disease
1,3-Didocosahexaenoyl glycerol (DG(22:6/0:0/22:6); 1,3-Didocosahexaenoin) is an ω-3 polyunsaturated fatty acid, which exhibits cardioprotective effects in rat myocardial ischemia/reperfusion (I/R) injury model through conjugation with Poly-l-glutamic acid (PGA) .

HY-10450S5

Dapagliflozin-13C6-1	Isotope-Labeled Compounds SGLT	Metabolic Disease Cancer
Dapagliflozin- ¹³C₆-1 is ¹³C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

HY-P5762A

Phoenixin-14 TFA PNX-14 TFA	Orphan GPCR Glutathione Peroxidase Ferroptosis ERK Toll-like Receptor (TLR) Sirtuin FOXO Akt PKA MyD88 Reactive Oxygen Species (ROS) Apoptosis NF-κB	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Phoenixin-14 (PNX-14) TFA is an endogenous neuropeptide with multiple biological activities, and serves as the endogenous ligand of GPR173. Phoenixin-14 TFA reduces ROS production by inhibiting the HMGB1/TLR4/MyD88/NF-κB signaling axis, thereby exerting antioxidant and mitochondrial protective effects. Phoenixin-14 TFA inhibits FOXO3 phosphorylation by upregulating SIRT3 expression, suppresses apoptosis, and improves myocardial systolic/diastolic function. Phoenixin-14 TFA resists ferroptosis by activating the ATF4/SLC7A11/GPX4 axis; it activates ERK1/2 phosphorylation via GPR173. Phoenixin-14 TFA can be used in researches on neuroprotection, diabetes, cardiomyopathy, reproductive protection and so on .

HY-10450S3

Dapagliflozin-13C6 BMS-512148-¹³C₆	Isotope-Labeled Compounds	Metabolic Disease Cancer
Dapagliflozin- ¹³C₆ (BMS-512148- ¹³C₆) is ¹³C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

HY-10450S2

Dapagliflozin-d4 BMS-512148-d₄	Isotope-Labeled Compounds SGLT	Metabolic Disease Cancer
Dapagliflozin-d₄ (BMS-512148-d₄) is deuterium labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

HY-125773R

β-cyano-L-Alanine (Standard) Beta-cyano-l-alanine (Standard)	Endogenous Metabolite Reference Standards	Neurological Disease
β-cyano-L-Alanine (Standard) is the analytical standard of β-cyano-L-Alanine. This product is intended for research and analytical applications. β-cyano-L-Alanine (Beta-cyano-l-alanine), a nitrile of widespread occurrence in higher plants, is enzymatically produced by cyanoalanine synthase from cyanide and cysteine as substrates . β-cyano-L-Alanine abolishes the protective effect of ethanol on cerebral ischemia/reperfusion (I/R) injury .

HY-118530R

Bucillamine (Standard) SA96 (Standard); Thiobutarit (Standard)	Reference Standards VEGFR	Cardiovascular Disease Inflammation/Immunology
Bucillamine (Standard) is the analytical standard of Bucillamine. This product is intended for research and analytical applications. Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic agent with antiangiogenic properties. Bucillamine can protect against Ischemia/reperfusion (I/R) injury in high-risk organ transplants. Bucillamine inhibits the production of VEGF. Bucillamine can be used for the research of choroidal neovascularization (CNV) and rheumatoid arthritis (RA) .

HY-169059

Ferroptosis-IN-12	Ferroptosis	Inflammation/Immunology
Ferroptosis-IN-12 (Cpd-A1) is a ferroptosis inhibitor. Ferroptosis-IN-12 exhibits effective ferroptosis inhibition in Erastin (HY-15763)-treated mouse tubular epithelial cells (mTECs) and improves kidney function, alleviates renal tubular damage, and reduces inflammation in a dose-dependent manner in acute kidney injury (AKI) mouse models induced by ischemia/reperfusion (I/R) or cecal ligation and puncture (CLP). Ferroptosis-IN-12 demonstrates good plasma stability and high distribution in kidney tissues in pharmacokinetic studies in mice. Ferroptosis-IN-12 holds promise for research in the field of acute kidney injury (AKI) .

HY-P5875

P4pal10	Protease Activated Receptor (PAR)	Cardiovascular Disease Inflammation/Immunology
P4pal10 is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 ameliorates the injury in mice myocardial ischemia/reperfusion (I/R) models .

HY-N0615R

Notoginsenoside R1 (Standard) Sanchinoside R1 (Standard); Sanqi glucoside R1 (Standard)	Reference Standards Amyloid-β Apoptosis	Others
Notoginsenoside R1 (Standard) is the analytical standard of Notoginsenoside R1. This product is intended for research and analytical applications. Notoginsenoside R1 (Sanchinoside R1), a saponin, is isolated from P. notoginseng. Notoginsenoside R1 exhibits anti-oxidation, anti-inflammatory, anti-angiogenic, and anti-apoptosis activities. Notoginsenoside R1 provides cardioprotection against ischemia/reperfusion (I/R) injury. Notoginsenoside R1 also provides neuroprotection in H2O2-induced oxidative damage in PC12 cells .

HY-N0272R

Eleutheroside E (Standard)	Reference Standards Others	Inflammation/Immunology
Eleutheroside E (Standard) is the analytical standard of Eleutheroside E. This product is intended for research and analytical applications. Eleutheroside E is an important component of Eleutheroside and has antioxidant, anti-fatigue, anti-inflammatory, antibacterial, immunomodulatory and cardioprotective effects. Eleutheroside E may inhibit the MAPK signaling pathway, thereby inhibiting H/R-induced NF-κB activation and oxidative stress, reducing metabolic reprogramming, and protecting myocardium from ischemia-reperfusion (I/R) injury. Eleutheroside E also counteracts the effects of high altitude hypobaric hypoxia (HAHI) by inhibiting inflammation and pyroptosis .

HY-10450AR

Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard) BMS-512148 (2S)-1,2-propanediol, hydrate (Standard)	Reference Standards SGLT	Metabolic Disease Cancer
Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard) is the analytical standard of Dapagliflozin ((2S)-1,2-propanediol, hydrate). This product is intended for research and analytical applications. Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury .

製品番号	製品名	Type